Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

1399312

registered interest
date	04/01/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment his Department has made of the efficacy of the Valneva covid-19 vaccine; and what steps he is taking to introduce that vaccine for people who cannot take the Pfizer, Astra-Zeneca or Moderna vaccines for ethical reasons.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	97052
answer	answer is ministerial correction date of answer 12/01/2022 answer text <p>The supply agreement between the government and Valneva was terminated in September 2021 and therefore this vaccine will not form part of the UK portfolio. Although Valneva have received their Phase III preliminary results and submitted their trial data to the MHRA, the company has not yet gained approval from the regulator. <br> <br> The UK Government has taken a portfolio approach to vaccine supply for regulated vaccines. The UK has sufficient supply now for the current booster campaign, as well as continuation of the primary vaccination programme.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/01/2022 09:50:06 answering member 4020 label Biography information for George Freeman
tabling member	4667 label Biography information for Mike Amesbury

1399403

registered interest
date	04/01/2022
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, whether foetal cells were used in the development of covid-19 vaccines.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	97053
answer	answer is ministerial correction date of answer 12/01/2022 answer text <p>Approved U.K. COVID-19 vaccines do not contain any human foetal tissue.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/01/2022 09:47:59 answering member 4020 label Biography information for George Freeman
tabling member	4667 label Biography information for Mike Amesbury

1363463

registered interest
date	26/10/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what assessment his Department has made of the feasibility of introducing nasal vaccines as part of the Government's covid-19 vaccination programme.
tabling member constituency	Weaver Vale
tabling member printed	Mike Amesbury
uin	63867
answer	answer is ministerial correction date of answer 01/11/2021 answer text <p>The Government’s approach to seeking a vaccine for COVID-19 has, from the outset, been to take a portfolio approach to vaccine procurement. This has allowed the Government to secure access to six different vaccine candidates across three vaccine types and from a range of developers. The aim is to ensure that the UK has access to the most promising vaccines currently in development, should any of these prove safe and effective.</p><p> </p><p>While there are currently no approved nasal vaccines for COVID-19, the Government continues to engage with the market as new vaccines and vaccine technologies gain approval.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 01/11/2021 17:21:55 answering member 4020 label Biography information for George Freeman
tabling member	4667 label Biography information for Mike Amesbury